GlassScriptPhysician profile
Ivonne Herrera
NPI 1992856785
$8,838.54
in general payments reported to CMS, 2019-2025
33 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $95.82 · 2021: $214 · 2022: $847 · 2023: $2,044 · 2024: $1,965 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,742 · Education: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,742.42 |
| Education | $480.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,386.71 | 2019-2025 | |
| Janssen Biotech, INC. | $1,125.07 | 2019-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $840.60 | 2022-2025 | Acthar |
| Amgen INC. | $738.46 | 2019-2025 | Evenity, Prolia, Avsola |
| Pfizer INC. | $704.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $631.66 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $529.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $431.06 | 2019-2025 | Benlysta |
| Ucb, INC. | $355.76 | 2019-2025 | Cimzia, Bimzelx |
| Pacira Therapeutics, INC. | $349.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $271.08 | 2019-2025 | Orencia |
| Janssen Scientific Affairs, LLC | $247.20 | 2019-2024 | Tremfya |
| Lilly USA, LLC | $190.64 | 2019-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $141.03 | 2023-2025 | Strensiq |
| Radius Health, INC. | $115.24 | 2022-2025 | Tymlos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $106.63 | 2021-2025 | Actemra, Xolair |
| Aurinia Pharma U.S., INC. | $88.27 | 2023-2025 | Lupkynis |
| Organon LLC | $85.97 | 2022-2025 | Renflexis, Hadlima |
| Horizon Therapeutics Plc | $80.56 | 2022-2023 | Krystexxa |
| Invivyd INC | $53.06 | 2025 | Pemgarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.15 | 2019 | |
| Merck Sharp & Dohme LLC | $45.96 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $43.08 | 2019 | |
| Sobi, INC | $42.76 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $32.04 | 2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $30.67 | 2025 | |
| Genzyme Corporation | $24.92 | 2025 | |
| Pharming Healthcare, INC. | $24.21 | 2023 | Ruconest |
| Medtronic, INC. | $20.47 | 2021 | |
| Lundbeck LLC | $16.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.81 | 2019 | |
| Celgene Corporation | $12.54 | 2019 | |
| Orthogenrx INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivonne Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.